Perpetual Medicines Licenses First Clinical Candidate Peptide Drug to Third Rock Ventures-Backed Entity

▲9July 4-5   CBI Biopharmaceutical Innovation Expo Scan the QR code to register

Note:This article does not constitute any investment advice or suggestions; please refer to official/company announcements for accuracy.This article is intended solely for the introduction of drugs related to medical health and does not constitute a recommendation for treatment plans (if involved), nor does it represent the platform's stance.Authorization is required for any article repost.

PharmaCircle DataMonitoring shows: In early June 2026, Perpetual Medicines, a wholly-owned subsidiary of TandemAI, made progress in its new drug development project jointly advanced with Third Rock Ventures (TRV), successfully delivering the first clinical candidate molecule. From project initiation to the identification of the candidate peptide drug molecule, the entire process took less than 18 months, triggering corresponding milestone payments. Details regarding the newly established pharmaceutical company and the target will be disclosed at an appropriate time.

Perpetual Medicines, as an independently operated entity under TandemAI, continues to be led by Dr. Bo Kerui, establishing a technological closed loop driven by the dual engines of “small molecules + peptides.”

It is reported that the company’s current pipeline includesMolecular TypeYes: small molecules, PROTACs, APC/Antibody-Peptide ConjugatesNovel peptide-antibody conjugates, etc.

Follow the "Yao Rong Quan" WeChat Official Account

References:

PharmCube Data;

https://www.perpetualmeds.com/about；

FDA/EMA；

NMPA；

https://www.sec.gov/Arch

ives/edgar/data；

https://www.businesswire.com；

https://lifescivoice.com；

https://www.globenewswire.com/n

ews-release；

https://www.businesswire.com/news/home；

Wait.